The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Life Expectancy

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Life Expectancy


Psychiatry related information on Life Expectancy

  • Those with significant co-morbidity, dementia, or a short life-expectancy should be treated with the lowest dose of levodopa required to maintain motor function [6].
  • The arbitrary thresholds currently applied for decision making at the Thoraxcenter are: no reperfusion therapy when the estimated gain in discounted life expectancy was < 1 month, streptokinase for 1-4 months and accelerated alteplase for a gain > or = 5 months [7].
  • Physical activity, from low to moderate to high, was significantly associated with more years of life expectancy in both smokers (9.5, 10.5, 12.9 years in men and 11.1, 12.6, 15.3 years in women at age 65) and nonsmokers (11.0, 14.4, 16.2 years in men and 12.7, 16.2, 18.4 years in women at age 65) [8].
  • Rett syndrome results from mutations in the X-linked methyl-CpG-binding protein 2 (MECP2) gene, which are nearly always lethal in males and lead to regression and reduced life expectancy in females [9].
  • Alzheimer's disease, CAD, and osteoporosis significantly affect the health and well-being of senior citizens in the United States. The fact that women have a longer life expectancy than men has led to the hypothesis that estrogen in some way imparts protection against these disease processes [10].

High impact information on Life Expectancy

  • Suitability for radical prostatectomy generally requires a clinically localized, potentially life-threatening tumor [as defined by Gleason grade, tumor stage, and serum prostate-specific antigen (PSA) level], a life expectancy of 10 years, and no serious co-morbid medical conditions [11].
  • The preponderance of data support the benefits of HRT in estrogen-deprived and menopausal women to reduce the risks of osteoporosis and cardiovascular disease and to enhance quality of life and life expectancy [12].
  • CONCLUSIONS: On the basis of a range of estimates of the incidence of cancer, prognosis, and efficacy of prophylactic surgery, our model suggests that prophylactic mastectomy provides substantial gains in life expectancy and prophylactic oophorectomy more limited gains for young women with BRCA1 or BRCA2 mutations [13].
  • As compared with streptokinase plus heparin, heparin alone provided 29 days of additional life expectancy over the predicted life expectancy of 20 years [14].
  • Treatment of the long-lived InR dwarfs with a juvenile hormone analog restores life expectancy toward that of wild-type controls [15].

Chemical compound and disease context of Life Expectancy


Biological context of Life Expectancy


Anatomical context of Life Expectancy


Associations of Life Expectancy with chemical compounds

  • Men with favorable baseline serum cholesterol levels had an estimated greater life expectancy of 3.8 to 8.7 years [31].
  • This benefit of isoniazid therapy increased patient life expectancy as much as 285 days [32].
  • Use of aerosolized pentamidine as a first-line agent would result in a modest increase in cost and a decrease in life expectancy [33].
  • CONCLUSION: Reflex HPV DNA testing provides the same or greater life expectancy benefits and is more cost-effective than other management strategies for women diagnosed as having ASC-US [34].
  • These findings indicate that although L-dopa may improve life expectancy during the first 6 years of therapy the protective effect subsequently declines [35].

Gene context of Life Expectancy


Analytical, diagnostic and therapeutic context of Life Expectancy


  1. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. Niederau, C., Fischer, R., Sonnenberg, A., Stremmel, W., Trampisch, H.J., Strohmeyer, G. N. Engl. J. Med. (1985) [Pubmed]
  2. Migration and granulomatous reaction after periurethral injection of polytef (Teflon). Malizia, A.A., Reiman, H.M., Myers, R.P., Sande, J.R., Barham, S.S., Benson, R.C., Dewanjee, M.K., Utz, W.J. JAMA (1984) [Pubmed]
  3. Diagnosis of hemochromatosis. Powell, L.W., George, D.K., McDonnell, S.M., Kowdley, K.V. Ann. Intern. Med. (1998) [Pubmed]
  4. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Jeyakumar, M., Butters, T.D., Cortina-Borja, M., Hunnam, V., Proia, R.L., Perry, V.H., Dwek, R.A., Platt, F.M. Proc. Natl. Acad. Sci. U.S.A. (1999) [Pubmed]
  5. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Tsevat, J., Weinstein, M.C., Williams, L.W., Tosteson, A.N., Goldman, L. Circulation (1991) [Pubmed]
  6. Dopamine agonist monotherapy in Parkinson's disease. Clarke, C.E., Guttman, M. Lancet (2002) [Pubmed]
  7. Estimated gain in life expectancy. A simple tool to select optimal reperfusion treatment in individual patients with evolving myocardial infarction. Boersma, H., van der Vlugt, M.J., Arnold, A.E., Deckers, J.W., Simoons, M.L. Eur. Heart J. (1996) [Pubmed]
  8. Smoking, physical activity, and active life expectancy. Ferrucci, L., Izmirlian, G., Leveille, S., Phillips, C.L., Corti, M.C., Brock, D.B., Guralnik, J.M. Am. J. Epidemiol. (1999) [Pubmed]
  9. Rett syndrome from quintuple and triple deletions within the MECP2 deletion hotspot region. Lebo, R.V., Ikuta, T., Milunsky, J.M., Milunsky, A. Clin. Genet. (2001) [Pubmed]
  10. Making a decision about ERT/HRT. Evidence to consider in initiating and continuing protective therapy. Nerhood, R.C. Postgraduate medicine. (2001) [Pubmed]
  11. Contemporary results of anatomic radical prostatectomy. Catalona, W.J., Ramos, C.G., Carvalhal, G.F. CA: a cancer journal for clinicians. (1999) [Pubmed]
  12. Hormone replacement therapy in the menopause: a pro opinion. Smith, H.O., Kammerer-Doak, D.N., Barbo, D.M., Sarto, G.E. CA: a cancer journal for clinicians. (1996) [Pubmed]
  13. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. Schrag, D., Kuntz, K.M., Garber, J.E., Weeks, J.C. N. Engl. J. Med. (1997) [Pubmed]
  14. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. O'Meara, J.J., McNutt, R.A., Evans, A.T., Moore, S.W., Downs, S.M. N. Engl. J. Med. (1994) [Pubmed]
  15. A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Tatar, M., Kopelman, A., Epstein, D., Tu, M.P., Yin, C.M., Garofalo, R.S. Science (2001) [Pubmed]
  16. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Neufeld, E.J. Blood (2006) [Pubmed]
  17. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Facon, T., Mary, J.Y., Pégourie, B., Attal, M., Renaud, M., Sadoun, A., Voillat, L., Dorvaux, V., Hulin, C., Lepeu, G., Harousseau, J.L., Eschard, J.P., Ferrant, A., Blanc, M., Maloisel, F., Orfeuvre, H., Rossi, J.F., Azaïs, I., Monconduit, M., Collet, P., Anglaret, B., Yakoub-Agha, I., Wetterwald, M., Eghbali, H., Vekemans, M.C., Maisonneuve, H., Troncy, J., Grosbois, B., Doyen, C., Thyss, A., Jaubert, J., Casassus, P., Thielemans, B., Bataille, R. Blood (2006) [Pubmed]
  18. Isoniazid preventive therapy in areas of high isoniazid resistance. Sterling, T.R., Brehm, W.T., Frieden, T.R. Arch. Intern. Med. (1995) [Pubmed]
  19. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Gage, B.F., Cardinalli, A.B., Owens, D.K. Arch. Intern. Med. (1996) [Pubmed]
  20. Individualizing therapy to prevent long-term consequences of estrogen deficiency in postmenopausal women. Col, N.F., Pauker, S.G., Goldberg, R.J., Eckman, M.H., Orr, R.K., Ross, E.M., Wong, J.B. Arch. Intern. Med. (1999) [Pubmed]
  21. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Suh, T.T., Holmbäck, K., Jensen, N.J., Daugherty, C.C., Small, K., Simon, D.I., Potter, S., Degen, J.L. Genes Dev. (1995) [Pubmed]
  22. The cost-effectiveness of preventing AIDS-related opportunistic infections. Freedberg, K.A., Scharfstein, J.A., Seage, G.R., Losina, E., Weinstein, M.C., Craven, D.E., Paltiel, A.D. JAMA (1998) [Pubmed]
  23. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database. Adams, P.C., Gregor, J.C., Kertesz, A.E., Valberg, L.S. Gastroenterology (1995) [Pubmed]
  24. Cysteine 64 of Ref-1 is not essential for redox regulation of AP-1 DNA binding. Ordway, J.M., Eberhart, D., Curran, T. Mol. Cell. Biol. (2003) [Pubmed]
  25. Reduced penetrance of the Huntington's disease mutation. McNeil, S.M., Novelletto, A., Srinidhi, J., Barnes, G., Kornbluth, I., Altherr, M.R., Wasmuth, J.J., Gusella, J.F., MacDonald, M.E., Myers, R.H. Hum. Mol. Genet. (1997) [Pubmed]
  26. Long-term studies on carcinogenicity and promoting effect of phenylbutazone in DONRYU rats. Meakawa, A., Onodera, H., Tanigawa, H., Furuta, K., Kanno, J., Matsuoka, C., Ogiu, T., Hayashi, Y. J. Natl. Cancer Inst. (1987) [Pubmed]
  27. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. Azzouz, M., Le, T., Ralph, G.S., Walmsley, L., Monani, U.R., Lee, D.C., Wilkes, F., Mitrophanous, K.A., Kingsman, S.M., Burghes, A.H., Mazarakis, N.D. J. Clin. Invest. (2004) [Pubmed]
  28. Human endothelial cell life extension by telomerase expression. Yang, J., Chang, E., Cherry, A.M., Bangs, C.D., Oei, Y., Bodnar, A., Bronstein, A., Chiu, C.P., Herron, G.S. J. Biol. Chem. (1999) [Pubmed]
  29. Population kinetics of precursors of IL 2-producing peripheral T lymphocytes: evidence for short life expectancy, continuous renewal, and post-thymic expansion. Rocha, B.B. J. Immunol. (1987) [Pubmed]
  30. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Shepherd, F.A., Cormier, Y., Burkes, R., Evans, W.K., Goss, G., Klimo, P., Feld, R., Taylor, M. Semin. Oncol. (1997) [Pubmed]
  31. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. Stamler, J., Daviglus, M.L., Garside, D.B., Dyer, A.R., Greenland, P., Neaton, J.D. JAMA (2000) [Pubmed]
  32. Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis. Jordan, T.J., Lewit, E.M., Montgomery, R.L., Reichman, L.B. JAMA (1991) [Pubmed]
  33. Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. Castellano, A.R., Nettleman, M.D. JAMA (1991) [Pubmed]
  34. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. Kim, J.J., Wright, T.C., Goldie, S.J. JAMA (2002) [Pubmed]
  35. Effect of L-dopa on course of Parkinson's disease. Curtis, L., Lees, A.J., Stern, G.M., Marmot, M.G. Lancet (1984) [Pubmed]
  36. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Hateboer, N., v Dijk, M.A., Bogdanova, N., Coto, E., Saggar-Malik, A.K., San Millan, J.L., Torra, R., Breuning, M., Ravine, D. Lancet (1999) [Pubmed]
  37. The OLD-1 positive regulator of longevity and stress resistance is under DAF-16 regulation in Caenorhabditis elegans. Murakami, S., Johnson, T.E. Curr. Biol. (2001) [Pubmed]
  38. Heat stress-induced life span extension in yeast. Shama, S., Lai, C.Y., Antoniazzi, J.M., Jiang, J.C., Jazwinski, S.M. Exp. Cell Res. (1998) [Pubmed]
  39. Polycystic liver and kidney diseases. Tahvanainen, E., Tahvanainen, P., Kääriäinen, H., Höckerstedt, K. Ann. Med. (2005) [Pubmed]
  40. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. MacLennan, I.C., Chapman, C., Dunn, J., Kelly, K. Lancet (1992) [Pubmed]
  41. Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians. Coley, C.M., Barry, M.J., Fleming, C., Fahs, M.C., Mulley, A.G. Ann. Intern. Med. (1997) [Pubmed]
  42. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia. Liberato, N.L., Quaglini, S., Barosi, G. J. Clin. Oncol. (1997) [Pubmed]
  43. Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective. Sarasin, F.P., Majno, P.E., Llovet, J.M., Bruix, J., Mentha, G., Hadengue, A. Hepatology (2001) [Pubmed]
  44. Evaluation of life expectancy in selection of patients undergoing percutaneous cervical cordotomy or subarachnoid phenol block for pain control of costopleural syndrome. Orlandini, G. Pain (1995) [Pubmed]
WikiGenes - Universities